Company Overview
iTonic Holdings Ltd., operating under the ticker ITOC, functions as a healthcare solutions provider dedicated to developing and commercializing specialized treatment software and devices for brachytherapy. This proprietary technology focuses on treatment planning systems that facilitate radioactive particle implantation, a form of radiotherapy utilized for treating cancer patients by placing radioactive sources within the body. The company operates within the broader Healthcare sector and specifically within the Medical Devices industry, positioning itself at the intersection of advanced oncology technology and medical hardware manufacturing. Its current market capitalization stands at $9.74M, while its trailing twelve-month revenue is recorded at $305,215, supported by an organizational structure of 10 employees. The combination of a sub-$10M market cap and annual revenue under $310,000 indicates that the company is a micro-cap entity with a very small operational footprint relative to its industry peers.
Financial Health
The company reported revenue of $305,215 for the trailing twelve months, yet this figure contrasts sharply with a net income of $-2,412,952 and an EBITDA of $-2,523,650. The substantial gap between the positive revenue of $305,215 and the negative net income of $-2,412,952 reveals a severe cost structure where operating expenses significantly exceed total sales, resulting in a loss greater than eight times the revenue generated. Free cash flow stands at $-2,674,562, indicating that the company is burning cash at a rate that exceeds its revenue generation, which severely limits its financial flexibility and ability to fund operations without external capital. Three distinct margin metrics further illustrate this financial distress: the gross margin is 82.9%, the operating margin is -3081.9%, and the profit margin is 0.0%. While the high gross margin of 82.9% suggests efficient production costs relative to the price of the device or software, the negative operating margin of -3081.9% and a profit margin of 0.0% confirm that overhead costs are unsustainable at the current revenue scale. The balance sheet shows a cash position of $3.21M against total debt of $139,595, supported by a debt-to-equity ratio of 2.95. Despite the low absolute debt level, the high debt-to-equity ratio of 2.95 suggests a leveraged capital structure that is unusual for a company with minimal assets, though the absolute cash reserves provide a buffer against interest obligations. The current ratio is 11.69, which technically indicates strong short-term liquidity as current assets vastly exceed current liabilities, though this metric is often skewed in micro-cap firms by non-cash current assets or inventory valuation issues. Return on Equity is -101.6% and Return on Assets is -49.0%, metrics that reveal management is currently destroying value rather than generating returns for shareholders or efficiently utilizing the asset base.
Valuation Assessment
Trailing P/E and forward P/E are both listed as N/A due to the company's negative earnings, which renders traditional price-to-earnings valuation metrics inapplicable for assessing value based on profitability. The price-to-book ratio is 1.42, indicating that the market values the company at 1.42 times its book value, suggesting a premium over the net asset value despite the absence of earnings to support such a multiple. The price-to-sales ratio is 31.90, while the EV/EBITDA stands at -1.45; these alternative metrics suggest that the market is pricing in significant future turnaround expectations or is valuing the company primarily on its asset base rather than its earnings power. The stock has experienced extreme volatility, trading between a 52-week high of $32.00 and a 52-week low of $0.27. The current price sits significantly below the 52-week high of $32.00, reflecting a substantial decline from the recent trading peak, while remaining well above the absolute low of $0.27. The beta value is listed as N/A, meaning there is insufficient historical data or market depth to calculate a reliable measure of the stock's price volatility relative to the broader market.
Growth & Income
Revenue growth year-over-year is -67.9%, while earnings growth year-over-year is N/A due to the lack of positive prior period earnings for comparison. The negative revenue growth of -67.9% indicates a contraction in sales, and since earnings are negative, it is impossible to determine if earnings are growing faster or slower than revenue in a traditional sense; however, the decline in revenue exacerbates the existing negative earnings situation. As a non-dividend payer, the company does not distribute a dividend yield, which is N/A, and maintains a payout ratio of 0.0%. This 0.0% payout ratio implies that the company retains all earnings—or in this case, losses—reinvesting them into growth initiatives or operational restructuring rather than paying dividends to shareholders. The overall growth and income profile for iTonic Holdings Ltd. is characterized by negative revenue expansion, a lack of profitability, and an absence of dividend income, presenting a high-risk investment scenario typical of early-stage or distressed medical device companies.